This inventor holds 1 USPTO granted patent. Top assignee: Mcgill University. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: Paul Campbell - Innovator in Cancer Research
Introduction
Paul Campbell is a notable inventor based in Oshawa, Canada. He has made significant contributions to the field of cancer research through his innovative work on oligonucleotide inhibitors. His research focuses on the inhibition of MBD2/DNA demethylase, which has important implications for cancer therapy.
Latest Patents
Paul Campbell holds a patent for "Oligonucleotide inhibitors of MBD2/DNA demethylase and uses thereof." This patent describes oligonucleotide inhibitors that effectively inhibit the expression of mammalian MBD2/DNA demethylase (MBD2/dMTase). These inhibitors can be utilized to inhibit the growth or proliferation of tumor cells both in vitro and in vivo. Furthermore, the patent outlines the use of these oligonucleotide inhibitors in cancer treatment and methods for identifying potential target genes for cancer therapy or diagnosis.
Career Highlights
Paul Campbell is affiliated with McGill University, where he continues to advance his research in the field of molecular biology and cancer treatment. His work has garnered attention for its potential to improve therapeutic strategies for cancer patients.
Collaborations
One of his notable collaborators is Moshe Szyf, with whom he has worked on various research projects related to DNA demethylation and cancer.
Conclusion
Paul Campbell's innovative research and patent contributions are paving the way for new cancer treatment methodologies. His work exemplifies the critical role of inventors in advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile